These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 6682703)
1. Lack of inhibition by oxipurinol of 5-FU toxicity against human tumor cell lines. Garewal HS; Ahmann FR; Alberts DS Cancer Treat Rep; 1983 May; 67(5):495-8. PubMed ID: 6682703 [TBL] [Abstract][Full Text] [Related]
2. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534 [TBL] [Abstract][Full Text] [Related]
3. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells. Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987 [TBL] [Abstract][Full Text] [Related]
4. Lack of dexamethasone effect on the antitumor activity of cisplatin. Aapro MS; Alberts DS; Serokman R Cancer Treat Rep; 1983 Nov; 67(11):1013-7. PubMed ID: 6685569 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon. Tisman G; Wu SJ Cancer Treat Rep; 1980; 64(8-9):829-35. PubMed ID: 7448820 [TBL] [Abstract][Full Text] [Related]
6. Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts. Houghton JA; Houghton PJ Cancer Treat Rep; 1982 May; 66(5):1201-6. PubMed ID: 7083222 [TBL] [Abstract][Full Text] [Related]
7. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. Ojima E; Inoue Y; Watanabe H; Hiro J; Toiyama Y; Miki C; Kusunoki M Oncol Rep; 2006 Nov; 16(5):1085-91. PubMed ID: 17016597 [TBL] [Abstract][Full Text] [Related]
8. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow. Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208 [TBL] [Abstract][Full Text] [Related]
9. Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines. Bjelogrlić SK; Srdić T; Radulović S J BUON; 2007; 12(1):71-6. PubMed ID: 17436405 [TBL] [Abstract][Full Text] [Related]
10. 5-FU and allopurinol: toxicity modulation and phase II results in colon cancer. Kroener JF; Saleh F; Howell SB Cancer Treat Rep; 1982 May; 66(5):1133-7. PubMed ID: 7083215 [TBL] [Abstract][Full Text] [Related]
11. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection. Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145 [TBL] [Abstract][Full Text] [Related]
12. Modulation of 5-fluorouracil toxicity by allopurinol in man. Howell SB; Wung WE; Taetle R; Hussain F; Romine JS Cancer; 1981 Sep; 48(6):1281-9. PubMed ID: 7023652 [TBL] [Abstract][Full Text] [Related]
13. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649 [TBL] [Abstract][Full Text] [Related]
14. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate. Das JR; Fryar EB; Green S; Southerland WM; Bowen D Anticancer Res; 2006; 26(6B):4279-86. PubMed ID: 17201145 [TBL] [Abstract][Full Text] [Related]
15. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma]. Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362 [TBL] [Abstract][Full Text] [Related]
17. Dual effects of folinic acid in 5-fluorouracil induced killing of human tumor cell lines in vitro. Blomgren H; Edler D; Hallström M; Ragnhammar P Anticancer Res; 1996; 16(5A):2713-7. PubMed ID: 8917376 [TBL] [Abstract][Full Text] [Related]
18. Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil. Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M Anticancer Res; 1999; 19(5B):3837-40. PubMed ID: 10628320 [TBL] [Abstract][Full Text] [Related]
19. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy. Fryar EB; Das JR; Davis JH; Desoto JA; Laniyan I; Southerland WM; Bowen D Anticancer Res; 2006; 26(3A):1861-7. PubMed ID: 16827118 [TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha. Greenblatt MS; Mangalik A; Ferguson J; Elias L Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]